Ann Lab Med.  2024 Sep;44(5):463-466. 10.3343/alm.2023.0468.

Comparison of Target- and IgG-Enrichment Strategies to Measure Adalimumab Concentrations in Human Plasma Using an Immunocapture-Liquid Chromatography-High-Resolution Mass Spectrometry Platform

• Ding X
• Zhu S
• Liu L
• Liu X
• Zhu K
• Miao L

• KMID: 2559155
• DOI: http://doi.org/10.3343/alm.2023.0468

Figure

• 

  Fig. 1 Representative chromatograms of two surrogate peptides from spiked and blank plasma samples. Chromatograms of APY peptide (APYTFGQGTK, A) and SIL-APY peptide (B) in spiked sample (1 μg/mL). Blank chromatograms of APY peptide (C) and SIL-APY peptide (D). Chromatograms of GLE peptide (GLEWVSAITWNSGHIDYADSVEGR, E) and SIL-GLE peptide (F) in spiked sample (1 μg/mL). Blank chromatograms of GLE peptide (G) and SIL-GLE peptide (H). 1 μg/mL of adalimumab and 5 μg/mL of internal standard. Abbreviations: AA, auto area; ADL, adalimumab; DB, double blank; RT, retention time; SIL, stable isotope-labeled.

• 

  Fig. 2 Method comparisons for adalimumab quantification. (A) Passing–Bablok regression plot of adalimumab concentrations determined using protein-A immunocapture LC-HRMS and TNF-α immunocapture LC-HRMS in ADA-negative samples represented using open circles (N=23). The red dots represent ADA-positive samples (N=8), and the solid and dashed lines indicate the regression line and confidence interval. (B) Comparison of the adalimumab concentrations obtained using protein-A immunocapture LC-HRMS (left), TNF-α immunocapture LC-HRMS (middle), and in-house ELISA (right) in 8 ADA-positive samples. (C) Scatter plot showing the positive relationship between the ratio of adalimumab concentrations obtained using protein-A enrichment and TNF-α enrichment LC-HRMS and ADA concentration (signal-to-negative ratio). Red line indicates the linear regression line (R2=0.61, P=0.02). (D) Passing–Bablok regression plot of adalimumab concentrations determined using in-house ELISA and TNF-α immunocapture LC-HRMS (N=31). Abbreviations: ADA, anti-drug antibodies; LC-HRMS, liquid chromatography high-resolution mass spectrometry; NS, not significant; S/N, signal to noise ratio; TNF, tumor necrosis factor.

Reference

References

1. Papamichael K, Afif W, Drobne D, Dubinsky MC, Ferrante M, Irving PM, et al. 2022; Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. Lancet Gastroenterol Hepatol. 7:171–85. DOI: 10.1016/S2468-1253(21)00223-5. PMID: 35026171.

2. EI Amrani M, Donners AAM, Hack CE, Huitema ADR, van Maarseveen EM. 2019; Six-step workflow for the quantification of therapeutic monoclonal antibodies in biological matrices with liquid chromatography mass spectrometry - a tutorial. Anal Chim Acta. 1080:22–34. DOI: 10.1016/j.aca.2019.05.076. PMID: 31409472.

3. Bartelds GM, Krieckaert CLM, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, et al. 2011; Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 305:1460–8. DOI: 10.1001/jama.2011.406. PMID: 21486979.

4. Ding X, Zhu R, Wu J, Xue L, Gu M, Miao L. 2020; Early adalimumab and anti-adalimumab antibody levels for prediction of primary nonresponse in ankylosing spondylitis patients. Clin Transl Sci. 13:547–54. DOI: 10.1111/cts.12738. PMID: 31961477. PMCID: PMC7214645. PMID: 5e8b18d083ad4ac5a2586d3789853132.

5. Jordan G, Onami I, Heinrich J, Staack RF. 2017; Evaluation of the potential use of hybrid LC-MS/MS for active drug quantification applying the 'free analyte QC concept'. Bioanalysis. 9:1705–17. DOI: 10.4155/bio-2017-0158. PMID: 28952783.

6. Iwamoto N, Hamada A, Shimada T. 2018; Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis. Anal Biochem. 540-1:30–7. DOI: 10.1016/j.ab.2017.11.002. PMID: 29128290.

7. Tron C, Lemaitre F, Bros P, Goulvestre C, Franck B, Mouton N, et al. 2022; Quantification of infliximab and adalimumab in human plasma by a liquid chromatography tandem mass spectrometry kit and comparison with two ELISA methods. Bioanalysis. 14:831–44. DOI: 10.4155/bio-2022-0057. PMID: 35735172.

8. Jenkins R, Duggan JX, Aubry AF, Zeng J, Lee JW, Cojocaru L, et al. 2015; Recommendations for validation of LC-MS/MS bioanalytical methods for protein biotherapeutics. AAPS J. 17:1–16. DOI: 10.1208/s12248-014-9685-5. PMID: 25392238. PMCID: PMC4287296.

9. Willeman T, Jourdil JF, Gautier-Veyret E, Bonaz B, Stanke-Labesque F. 2019; A multiplex liquid chromatography tandem mass spectrometry method for the quantification of seven therapeutic monoclonal antibodies: application for adalimumab therapeutic drug monitoring in patients with Crohn's disease. Anal Chim Acta. 1067:63–70. DOI: 10.1016/j.aca.2019.03.033. PMID: 31047150.